Overview

METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
To further evaluate and observe the efficacy and safety of solantinib combined with METR-NK neoadjuvant therapy for advanced epithelial ovarian cancer in patients with advanced epithelial ovarian cancer by using solantinib combined with METR-NK neoadjuvant therapy
Phase:
PHASE1
Details
Lead Sponsor:
Anhui Provincial Cancer Hospital